BEAM

SEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,773

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,063

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.15 to $86.99, inclusive.

SEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,164

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.88, inclusive.

SEC source: 0000899243-21-049634 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-049422 · doc4.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,253

Underlying: Common Stock · 25,104 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,773

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.00 to $86.74, inclusive.

SEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,421

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.99, inclusive.

SEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-049422 · doc4.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,357

Underlying: Common Stock · 4,289 shares

Expires 2029-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,773

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.00 to $85.69, inclusive.

SEC source: 0000899243-21-049422 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-22-004197 · doc4a.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 968,825

SEC source: 0000899243-21-043520 · doc4.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,133

Underlying: Common Stock · 13,133 shares

Expires 2031-11-05

F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date.

SEC source: 0000899243-21-039697 · doc4.xml · derivative · entry 10

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,645

Underlying: Common Stock · 27,700 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 183,000

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.07 to $85.31, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 183,400

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.98, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 190,966

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.08 to $83.98, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 200,829

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.97, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,033,525

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $85.03 to $85.32, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,034,226

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.005 to $84.98, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,044,670

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.04 to $83.98, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,058,076

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.465 to $82.995, inclusive.

SEC source: 0000899243-21-039697 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,061,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

SEC source: 0000899243-21-036829 · doc4.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,402

Underlying: Common Stock · 18,012 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with the Company through such dates.

SEC source: 0000899243-21-036829 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 7

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 1,744,221

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 304

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 969,342

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 2,293

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 0

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 16,153

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001703 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 4,611,205

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000899243-21-033848 · doc4.xml · derivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,345

Underlying: Common Stock · 12,000 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,033,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 203,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 203,300

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.04 to $100.99, inclusive.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 208,756

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $99.01 to $99.95, inclusive.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 218,460

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $98.33 to $98.99, inclusive.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 221,600

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $97.22 to $97.85, inclusive.

SEC source: 0000899243-21-033848 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 222,600

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $96.07 to $96.97, inclusive.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 153

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 7

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 950,485

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

F2 · ownership.nature: This amendment is being filed to include missing holdings from Table 1 by persons and entities whose shares are subject to reporting by the undersigned and report FMR LLC still subject to Section 16.

SEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 153

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 1,160,583

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 724

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 0

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 7,454

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001699 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 6,226,519

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 1,160,583

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 724

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.